AMAG Pharmaceuticals RSI
Cos'è RSI di AMAG Pharmaceuticals?
RSI di AMAG Pharmaceuticals, Inc. è 97.78
Qual è la definizione di RSI?
L'indice di forza relativa (RSI 14) è un indicatore di momentum che confronta l'entità dei guadagni e delle perdite in un determinato periodo di tempo per misurare la velocità e il cambiamento dei movimenti di prezzo di un titolo.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI di aziende nel Health Care settore su NASDAQ rispetto a AMAG Pharmaceuticals
Cosa fa AMAG Pharmaceuticals?
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
Aziende con rsi simili a AMAG Pharmaceuticals
- 6D Global Technologies ha RSI di 97.61
- MyFiziq ha RSI di 97.65
- Bio-Rad Laboratories ha RSI di 97.73
- Luen Wong ha RSI di 97.75
- Cadeler A/S ha RSI di 97.76
- Duesenberg Technologies ha RSI di 97.76
- AMAG Pharmaceuticals ha RSI di 97.78
- Arq ha RSI di 97.79
- Tritent International ha RSI di 97.82
- CenturyLink ha RSI di 97.83
- China Biologic Products Inc ha RSI di 97.83
- Better Capital PCC 2009 ha RSI di 97.88
- Elixinol Global ha RSI di 97.98